Literature DB >> 7495854

Lysophosphatidylcholine inhibits vesicles fusion induced by the NH2-terminal extremity of SIV/HIV fusogenic proteins.

I Martin1, J M Ruysschaert.   

Abstract

Intermediate lipid structures such as inverted micelles and interlamellar attachments are thought to play a crucial role in different biological processes like exocytosis, intracellular trafficking and viral infection. In the present study, we provide evidence that lipid mixing of large unilamellar lipid vesicles (LUV) mediated by the NH2-terminal sequence of the SIV gp32 and of HIV gp41 is inhibited by external addition of lysophosphatidylcholine (lysoPC) to LUV containing phosphatidylethanolamine in their lipid bilayer. Leakage experiments confirm that lysoPC enhances the stability of the lipids organization. The temperature dependence of the two processes as well as the complementary shape of PE and lysoPC suggest that the PE-lysoPC interaction is involved in the fusion inhibition and stabilization of the bilayer.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7495854     DOI: 10.1016/0005-2736(95)00171-4

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  11 in total

Review 1.  The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design.

Authors:  Marinieve Montero; Nienke E van Houten; Xin Wang; Jamie K Scott
Journal:  Microbiol Mol Biol Rev       Date:  2008-03       Impact factor: 11.056

2.  A broad-spectrum antiviral targeting entry of enveloped viruses.

Authors:  Mike C Wolf; Alexander N Freiberg; Tinghu Zhang; Zeynep Akyol-Ataman; Andrew Grock; Patrick W Hong; Jianrong Li; Natalya F Watson; Angela Q Fang; Hector C Aguilar; Matteo Porotto; Anna N Honko; Robert Damoiseaux; John P Miller; Sara E Woodson; Steven Chantasirivisal; Vanessa Fontanes; Oscar A Negrete; Paul Krogstad; Asim Dasgupta; Anne Moscona; Lisa E Hensley; Sean P Whelan; Kym F Faull; Michael R Holbrook; Michael E Jung; Benhur Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-28       Impact factor: 11.205

3.  Membrane fusion promoters and inhibitors have contrasting effects on lipid bilayer structure and undulations.

Authors:  T J McIntosh; K G Kulkarni; S A Simon
Journal:  Biophys J       Date:  1999-04       Impact factor: 4.033

4.  PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Authors:  Ana Maria Chamoun; Karuppiah Chockalingam; Michael Bobardt; Rudo Simeon; Jinhong Chang; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

5.  Secreted phospholipases A(2), a new class of HIV inhibitors that block virus entry into host cells.

Authors:  D Fenard; G Lambeau; E Valentin; J C Lefebvre; M Lazdunski; A Doglio
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

6.  Interaction of influenza virus fusion peptide with lipid membranes: effect of lysolipid.

Authors:  S Ohki; G A Baker; P M Page; T A McCarty; R M Epand; F V Bright
Journal:  J Membr Biol       Date:  2006-11-07       Impact factor: 1.843

7.  Fusion peptide from influenza hemagglutinin increases membrane surface order: an electron-spin resonance study.

Authors:  Mingtao Ge; Jack H Freed
Journal:  Biophys J       Date:  2009-06-17       Impact factor: 4.033

8.  SARS-CoV fusion peptides induce membrane surface ordering and curvature.

Authors:  Luis G M Basso; Eduardo F Vicente; Edson Crusca; Eduardo M Cilli; Antonio J Costa-Filho
Journal:  Sci Rep       Date:  2016-11-28       Impact factor: 4.379

Review 9.  Implications for lipids during replication of enveloped viruses.

Authors:  Robin B Chan; Lukas Tanner; Markus R Wenk
Journal:  Chem Phys Lipids       Date:  2010-03-15       Impact factor: 3.329

10.  Effect of membrane curvature-modifying lipids on membrane fusion by tick-borne encephalitis virus.

Authors:  Karin Stiasny; Franz X Heinz
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.